This is the first US Food and Drug Administration approval for a drug based solely on data from a basket study.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
In an increasingly diverse field of sequencing assays, Genentech researchers believe they have achieved notable sensitivity, with high multiplexing capability and relatively low cost.
A meta-analysis based on genotyping data for more than 400,000 people with or without the disease led to 17 new risk loci mined for candidate genes
In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.
At the Personalized Medicine World Conference, stakeholders and the former FDA commissioner discussed how regulation can advance personalized medicine amid political uncertainty.
The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.
The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.
The two partners hope to start a Phase I combination trial pairing Genentech's anti-PDL1 cancer immunotherapy Tecentriq with vaccines developed using BioNTech's IVAC Mutanome.
The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.